Bridge to Life Appoints David Castiglioni as Chief Commercial Officer to Head Global Commercial Operations and Lead the U.S. Commercialization of VitaSmart™

CHICAGO, Sept. 29, 2025 /PRNewswire/ -- Bridge to Life Ltd., a leader in organ preservation solutions and perfusion technology, today announced the appointment of David Castiglioni as Chief Commercial Officer (CCO). In this role, Mr. Castiglioni will be responsible for all global commercial operations, with an immediate focus on preparing for the U.S. launch of the VitaSmart™ Hypothermic Oxygenated Perfusion System upon FDA clearance. The United States represents the largest global market for machine perfusion technology.

Mr. Castiglioni brings nearly three decades of leadership experience in healthcare, medtech, and biotechnology. He has a proven record of building high-performing commercial teams, scaling early-stage ventures into global businesses, and driving transformative growth. Most notably, during his tenure at Intuitive Surgical, one of medtech's most notable success stories, he built and led commercial teams that drove adoption of the da Vinci surgical system, helping to establish the company as a market leader.

He has since served as CCO at Hyperfine, MediGO (acquired by CareDx), and Siren Care, where he consistently delivered rapid revenue growth and successful go-to-market strategies across the U.S., Europe, and Asia-Pacific.

"We are thrilled to welcome Dave to the Bridge to Life leadership team at such an important moment," said Don Webber, President and Chief Executive Officer of Bridge to Life. "His track record of building world-class commercial organizations—highlighted by his years at Intuitive—combined with his deep experience bringing creative product offerings to customers, makes him the ideal leader to guide the U.S. launch of VitaSmart™, and the next wave of growth for our complete transplantation solutions offerings."

"I am excited to join Bridge to Life as Chief Commercial Officer," said David Castiglioni. "VitaSmart™ has already demonstrated its value in Europe, and the upcoming U.S. launch represents a pivotal opportunity to bring this innovation to the world's largest transplant market. Based on my discussions with clinicians, the impact of VitaSmart™ on the transplant ecosystem has the potential to be nothing short of transformative, and I look forward to building a commercial strategy and organization that fully realizes that opportunity."

About Bridge to Life™ Ltd.

Bridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush®, and the VitaSmart™ Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation, and accessibility, the company partners with leading Transplant Centers and Organ Procurement Organizations worldwide.

VitaSmart™ is CE Marked and available for sale in several markets outside of the United States. VitaSmart™ is pending FDA clearance in the United States.

SOURCE Bridge to Life, Ltd.